Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)58.72bn
  • Net income in CHF11.50bn
  • Incorporated1966
  • Employees103.61k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttps://www.roche.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ROG:SWX since
announced
Transaction
value
LumiraDx International LtdAnnounced29 Dec 202329 Dec 2023Announced-5.26%--
LumiraDx Group LtdAnnounced29 Dec 202329 Dec 2023Announced-5.26%295.00m
Carmot Therapeutics IncDeal completed04 Dec 202304 Dec 2023Deal completed-4.13%3.10bn
Data delayed at least 15 minutes, as of Mar 28 2024 16:37 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lonza Group AG6.72bn654.00m40.23bn17.90k60.834.1329.545.998.888.8890.98130.870.39282.804.84--3.835.074.646.2129.0039.149.7514.521.2012.350.227530.587.943.92-46.17-0.030623.957.78
Merck KGaA20.42bn2.75bn69.19bn62.91k25.192.6715.413.396.506.5048.2761.360.43271.865.03333,709.505.845.647.207.2759.0361.8613.4912.970.891632.810.26949.26-5.577.19-15.0921.4014.7711.97
GSK plc34.52bn5.61bn80.61bn70.21k14.215.198.682.341.201.207.393.290.50911.574.20431,949.008.916.7413.9110.7172.4270.2917.5016.930.62410.990.584879.553.42-0.32215.797.105.47-10.32
Sanofi SA45.18bn5.25bn111.92bn87.99k21.151.5414.902.484.304.3037.0459.170.36691.535.51527,808.704.385.875.437.1669.3568.7811.9516.900.867566.190.198660.512.325.42-35.494.578.874.14
Roche Holding AG58.72bn11.50bn187.30bn103.61k16.066.2511.843.1914.3014.3073.0336.770.65741.915.19566,729.4013.8416.1220.8425.2473.3971.4821.0522.981.0420.770.467658.80-7.210.6494-7.431.9010.011.99
AstraZeneca plc41.31bn5.37bn188.41bn89.90k35.345.3418.414.563.023.0223.2420.010.46371.594.05403,722.806.033.348.474.6182.3979.6413.017.690.64276.340.4222143.063.2915.7181.1122.5422.471.10
Novartis AG42.07bn7.72bn191.33bn76.06k23.534.2412.424.553.716.4420.1420.580.42931.846.15553,120.107.898.5310.5711.2374.2472.9318.3722.680.93113.160.360567.207.570.277941.64-7.710.78086.19
Novo Nordisk A/S30.29bn10.91bn394.86bn63.37k47.3336.8733.2813.0318.6218.6251.6823.900.83591.274.033,665,157.0030.1229.1763.1258.6284.6083.9336.0333.550.6356--0.202250.1331.2615.7450.7116.7225.6718.20
Data as of Mar 28 2024. Currency figures normalised to Roche Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

16.01%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Mar 202425.65m3.65%
Norges Bank Investment Managementas of 31 Dec 202320.17m2.87%
UBS Asset Management Switzerland AGas of 05 Mar 202416.16m2.30%
BlackRock Fund Advisorsas of 07 Mar 202412.87m1.83%
Z�rcher Kantonalbank (Investment Management)as of 31 Jan 20249.02m1.28%
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 20247.64m1.09%
BlackRock Advisors (UK) Ltd.as of 07 Mar 20245.70m0.81%
Massachusetts Financial Services Co.as of 29 Feb 20245.51m0.78%
Geode Capital Management LLCas of 20 Mar 20245.00m0.71%
FIL Investments Internationalas of 08 Mar 20244.74m0.68%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.